Skip to main content

Table 2 Treatment outcomes of ASAQ and AL treatment, per-protocol analysis

From: Artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in Congolese children under 10 years old living in a suburban area: a randomized study

  ASAQ AL
Overall AA AS Overall AA AS
Number of patients, N 129 112 17 133 109 24
PCR uncorrected responses on day 28
 Lost to follow-up, N (%) 22 (17.1) 22 (19.6) 1 (5.9) 15 (11.3) 13 (11.9) 2 (8.3)
 Eligible, N (%) 107 (82.9) 90 (80.4) 16 (94.1) 118 (88.7) 96 (88.1) 22 (91.7)
 Failure, N (%) 10 (9.4) 9 (10.0) 1 (6.2) 12 (10.2) 10 (10.4) 2 (9.1)
 ETF, N (%) 0 0 0 0 0 0
 LCF, N (%) 5 (4.7) 4 (4.4) 1 (6.2) 5 (4.2) 5 (5.2) 0
 LPF, N (%) 5 (4.7) 5 (5.6) 0 7 (5.9) 5 (5.2) 2 (9.1)
 ACPR, N (%) 97 (90.6) 81 (90.0) 15 (93.8) 106 (89.8) 86 (89.6) 20 (90.9)
PCR corrected responses on day 28
 Loss of follow up + new infection, N (%) 30 (23.3) 28 (25.0) 2 (11.8) 23 (17.3) 20 (18.3) 3 (12.5)
 Eligible, N (%) 99 (76.7) 84 (75.0) 15 (88.2) 110 (82.7) 89 (81.7) 21 (87.5)
 Failure, N (%) 3 (3.0) 3 (3.6) 0 4 (3.6) 3 (3.3) 1 (4.8)
 ETF, N (%) 0 0 0 0 0 0
 ACPR, N (%) 96 (97.0) 81 (96.4) 15 (100) 106 (96.4) 86 (96.6) 20 (95.2)
 Recrudescence, N 3 3 0 4 3 1
 New infection, N 7 6 1 8 7 1
  1. ASAQ artesunate-amodiaquine, AL artemether-lumefantrine, ETF early treatment failure, LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical and parasitological response